JAB Acquisition I, a blank check company targeting marketing tech and customer acquisition platforms, filed on Tuesday with the SEC to raise up to $150 million in an initial public offering. The company plans to raise $150 million by offering 15 million units ...read more
Parabilis Medicines, a Phase 3-ready biotech developing engineered peptide therapies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. Parabilis Medicines is a clinical-stage biotech developing medicines that...read more
Oceanhawk Acquisition, a blank check company backed by investment firm OceanHawk, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to raise $150 million by offering 15 million units at $10. The company...read more
SPAC JAB Acquisition I files for a $150 million IPO, targeting marketing tech
JAB Acquisition I, a blank check company targeting marketing tech and customer acquisition platforms, filed on Tuesday with the SEC to raise up to $150 million in an initial public offering. The company plans to raise $150 million by offering 15 million units ...read more
Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO
Parabilis Medicines, a Phase 3-ready biotech developing engineered peptide therapies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. Parabilis Medicines is a clinical-stage biotech developing medicines that...read more
OceanHawk's SPAC Oceanhawk Acquisition decreases units offered by 25% ahead of $150 million IPO
Oceanhawk Acquisition, a blank check company backed by investment firm OceanHawk, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to raise $150 million by offering 15 million units at $10. The company...read more